Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys
Although dopamine D 3 receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D 3 receptor-preferring compounds. This study examined the behavioral effects of D 3 receptor-selective 4-phenylpiperazines with differing in v...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2011-02, Vol.36 (5), p.1104-1113 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1113 |
|---|---|
| container_issue | 5 |
| container_start_page | 1104 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 36 |
| creator | Blaylock, B L Gould, R W Banala, A Grundt, P Luedtke, R R Newman, A H Nader, M A |
| description | Although dopamine D
3
receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D
3
receptor-preferring compounds. This study examined the behavioral effects of D
3
receptor-selective 4-phenylpiperazines with differing
in vitro
functional profiles in adult male rhesus monkeys with a history of cocaine self-administration and controls.
In vitro
assays found that PG 619 (
N
-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) was a potent D
3
antagonist in the mitogenesis assay, but a fully efficacious agonist in the adenylyl cyclase assay, NGB 2904 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9
H
-fluorene-2-carboxamide HCl) was a selective D
3
antagonist, whereas CJB 090 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) exhibited a partial agonist profile in both
in vitro
assays. In behavioral studies, the D
3
preferential agonist quinpirole (0.03–1.0 mg/kg, i.v.) dose-dependently elicited yawns in both groups of monkeys. PG 619 and CJB 090 elicited yawns only in monkeys with an extensive history of cocaine, whereas NGB 2904 did not elicit yawns, but did antagonize quinpirole and PG 619-elicited yawning in cocaine-history monkeys. In another experiment, doses of PG 619 that elicited yawns did not alter response rates in monkeys self-administering cocaine (0.03–0.3 mg/kg per injection). Following saline extinction, cocaine (0.1 mg/kg) and quinpirole (0.1 mg/kg), but not PG 619 (0.1 mg/kg), reinstated cocaine-seeking behavior. When given before a cocaine prime, PG 619 decreased cocaine-elicited reinstatement. These findings suggest that (1) an incongruence between
in vitro
and
in vivo
assays, and (2) a history of cocaine self-administration can affect
in vivo
efficacy of D
3
receptor-preferring compounds PG 619 and CJB 090, which appear to be dependent on the behavioral assay. |
| doi_str_mv | 10.1038/npp.2010.248 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3070922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2293306511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2688-4f8e36094f68c567143f1c128492b89563f255db3931fe46ab60301ae4f5954b3</originalsourceid><addsrcrecordid>eNptkV1rFDEYhYModt165w8IgndOm6_JZG4E3VZbqAhWoXchk33TTZ1JpsnMwv57s-xSKXgVwnnecw4chN5RckYJV-dhHM8YKT8m1Au0oI0gleTi7iVaENXyinJ-d4Le5PxACK0bqV6jE0aZaiUhCzRcB9fPECzg6PAqWuMD4Cufp5h2OAY8bQB_gY3Z-phMjy-dAzvlPXwRRzPs6QuOf4KFsZxUt9AX3W-heA1jnMM6Yx_w9xj-wC6folfO9BneHt8l-v318tfqqrr58e169fmmskwqVQmngEvSCieVrWVDBXfUls6iZZ1qa8kdq-t1x1tOHQhpOkk4oQaEq9tadHyJPh18x7kbYG0hTKW8HpMfTNrpaLx-rgS_0fdxqzlpSMtYMXh_NEjxcYY86Yc4p1A6a1U3tGasJC7RxwNkU8w5gXsKoETvt9FlG73fRpdtCv7h6GmyNb1LJlifn26YIA0XTVO46sDlIoV7SP-y_-v7F7gsnJM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>857152260</pqid></control><display><type>article</type><title>Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys</title><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Blaylock, B L ; Gould, R W ; Banala, A ; Grundt, P ; Luedtke, R R ; Newman, A H ; Nader, M A</creator><creatorcontrib>Blaylock, B L ; Gould, R W ; Banala, A ; Grundt, P ; Luedtke, R R ; Newman, A H ; Nader, M A</creatorcontrib><description>Although dopamine D
3
receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D
3
receptor-preferring compounds. This study examined the behavioral effects of D
3
receptor-selective 4-phenylpiperazines with differing
in vitro
functional profiles in adult male rhesus monkeys with a history of cocaine self-administration and controls.
In vitro
assays found that PG 619 (
N
-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) was a potent D
3
antagonist in the mitogenesis assay, but a fully efficacious agonist in the adenylyl cyclase assay, NGB 2904 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9
H
-fluorene-2-carboxamide HCl) was a selective D
3
antagonist, whereas CJB 090 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) exhibited a partial agonist profile in both
in vitro
assays. In behavioral studies, the D
3
preferential agonist quinpirole (0.03–1.0 mg/kg, i.v.) dose-dependently elicited yawns in both groups of monkeys. PG 619 and CJB 090 elicited yawns only in monkeys with an extensive history of cocaine, whereas NGB 2904 did not elicit yawns, but did antagonize quinpirole and PG 619-elicited yawning in cocaine-history monkeys. In another experiment, doses of PG 619 that elicited yawns did not alter response rates in monkeys self-administering cocaine (0.03–0.3 mg/kg per injection). Following saline extinction, cocaine (0.1 mg/kg) and quinpirole (0.1 mg/kg), but not PG 619 (0.1 mg/kg), reinstated cocaine-seeking behavior. When given before a cocaine prime, PG 619 decreased cocaine-elicited reinstatement. These findings suggest that (1) an incongruence between
in vitro
and
in vivo
assays, and (2) a history of cocaine self-administration can affect
in vivo
efficacy of D
3
receptor-preferring compounds PG 619 and CJB 090, which appear to be dependent on the behavioral assay.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.2010.248</identifier><identifier>PMID: 21289600</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>631/92/436/2387 ; 692/699/476/5 ; Addictive behaviors ; Behavior ; Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Cocaine ; Dopamine ; Drug abuse ; Medical research ; Medical sciences ; Medicine ; Medicine & Public Health ; Monkeys & apes ; Neuropharmacology ; Neurosciences ; Original ; original-article ; Pharmacology ; Pharmacology. Drug treatments ; Pharmacotherapy ; Physiology ; Psychiatry ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2011-02, Vol.36 (5), p.1104-1113</ispartof><rights>American College of Neuropsychopharmacology 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Apr 2011</rights><rights>Copyright © 2011 American College of Neuropsychopharmacology 2011 American College of Neuropsychopharmacology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2688-4f8e36094f68c567143f1c128492b89563f255db3931fe46ab60301ae4f5954b3</citedby><cites>FETCH-LOGICAL-c2688-4f8e36094f68c567143f1c128492b89563f255db3931fe46ab60301ae4f5954b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070922/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070922/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24073477$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Blaylock, B L</creatorcontrib><creatorcontrib>Gould, R W</creatorcontrib><creatorcontrib>Banala, A</creatorcontrib><creatorcontrib>Grundt, P</creatorcontrib><creatorcontrib>Luedtke, R R</creatorcontrib><creatorcontrib>Newman, A H</creatorcontrib><creatorcontrib>Nader, M A</creatorcontrib><title>Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacol</addtitle><description>Although dopamine D
3
receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D
3
receptor-preferring compounds. This study examined the behavioral effects of D
3
receptor-selective 4-phenylpiperazines with differing
in vitro
functional profiles in adult male rhesus monkeys with a history of cocaine self-administration and controls.
In vitro
assays found that PG 619 (
N
-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) was a potent D
3
antagonist in the mitogenesis assay, but a fully efficacious agonist in the adenylyl cyclase assay, NGB 2904 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9
H
-fluorene-2-carboxamide HCl) was a selective D
3
antagonist, whereas CJB 090 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) exhibited a partial agonist profile in both
in vitro
assays. In behavioral studies, the D
3
preferential agonist quinpirole (0.03–1.0 mg/kg, i.v.) dose-dependently elicited yawns in both groups of monkeys. PG 619 and CJB 090 elicited yawns only in monkeys with an extensive history of cocaine, whereas NGB 2904 did not elicit yawns, but did antagonize quinpirole and PG 619-elicited yawning in cocaine-history monkeys. In another experiment, doses of PG 619 that elicited yawns did not alter response rates in monkeys self-administering cocaine (0.03–0.3 mg/kg per injection). Following saline extinction, cocaine (0.1 mg/kg) and quinpirole (0.1 mg/kg), but not PG 619 (0.1 mg/kg), reinstated cocaine-seeking behavior. When given before a cocaine prime, PG 619 decreased cocaine-elicited reinstatement. These findings suggest that (1) an incongruence between
in vitro
and
in vivo
assays, and (2) a history of cocaine self-administration can affect
in vivo
efficacy of D
3
receptor-preferring compounds PG 619 and CJB 090, which appear to be dependent on the behavioral assay.</description><subject>631/92/436/2387</subject><subject>692/699/476/5</subject><subject>Addictive behaviors</subject><subject>Behavior</subject><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Cocaine</subject><subject>Dopamine</subject><subject>Drug abuse</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monkeys & apes</subject><subject>Neuropharmacology</subject><subject>Neurosciences</subject><subject>Original</subject><subject>original-article</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacotherapy</subject><subject>Physiology</subject><subject>Psychiatry</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkV1rFDEYhYModt165w8IgndOm6_JZG4E3VZbqAhWoXchk33TTZ1JpsnMwv57s-xSKXgVwnnecw4chN5RckYJV-dhHM8YKT8m1Au0oI0gleTi7iVaENXyinJ-d4Le5PxACK0bqV6jE0aZaiUhCzRcB9fPECzg6PAqWuMD4Cufp5h2OAY8bQB_gY3Z-phMjy-dAzvlPXwRRzPs6QuOf4KFsZxUt9AX3W-heA1jnMM6Yx_w9xj-wC6folfO9BneHt8l-v318tfqqrr58e169fmmskwqVQmngEvSCieVrWVDBXfUls6iZZ1qa8kdq-t1x1tOHQhpOkk4oQaEq9tadHyJPh18x7kbYG0hTKW8HpMfTNrpaLx-rgS_0fdxqzlpSMtYMXh_NEjxcYY86Yc4p1A6a1U3tGasJC7RxwNkU8w5gXsKoETvt9FlG73fRpdtCv7h6GmyNb1LJlifn26YIA0XTVO46sDlIoV7SP-y_-v7F7gsnJM</recordid><startdate>20110202</startdate><enddate>20110202</enddate><creator>Blaylock, B L</creator><creator>Gould, R W</creator><creator>Banala, A</creator><creator>Grundt, P</creator><creator>Luedtke, R R</creator><creator>Newman, A H</creator><creator>Nader, M A</creator><general>Springer International Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20110202</creationdate><title>Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys</title><author>Blaylock, B L ; Gould, R W ; Banala, A ; Grundt, P ; Luedtke, R R ; Newman, A H ; Nader, M A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2688-4f8e36094f68c567143f1c128492b89563f255db3931fe46ab60301ae4f5954b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/92/436/2387</topic><topic>692/699/476/5</topic><topic>Addictive behaviors</topic><topic>Behavior</topic><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Cocaine</topic><topic>Dopamine</topic><topic>Drug abuse</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monkeys & apes</topic><topic>Neuropharmacology</topic><topic>Neurosciences</topic><topic>Original</topic><topic>original-article</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacotherapy</topic><topic>Physiology</topic><topic>Psychiatry</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blaylock, B L</creatorcontrib><creatorcontrib>Gould, R W</creatorcontrib><creatorcontrib>Banala, A</creatorcontrib><creatorcontrib>Grundt, P</creatorcontrib><creatorcontrib>Luedtke, R R</creatorcontrib><creatorcontrib>Newman, A H</creatorcontrib><creatorcontrib>Nader, M A</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blaylock, B L</au><au>Gould, R W</au><au>Banala, A</au><au>Grundt, P</au><au>Luedtke, R R</au><au>Newman, A H</au><au>Nader, M A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><stitle>Neuropsychopharmacol</stitle><date>2011-02-02</date><risdate>2011</risdate><volume>36</volume><issue>5</issue><spage>1104</spage><epage>1113</epage><pages>1104-1113</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>Although dopamine D
3
receptors have been associated with cocaine abuse, little is known about the consequences of chronic cocaine on functional activity of D
3
receptor-preferring compounds. This study examined the behavioral effects of D
3
receptor-selective 4-phenylpiperazines with differing
in vitro
functional profiles in adult male rhesus monkeys with a history of cocaine self-administration and controls.
In vitro
assays found that PG 619 (
N
-(3-hydroxy-4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) was a potent D
3
antagonist in the mitogenesis assay, but a fully efficacious agonist in the adenylyl cyclase assay, NGB 2904 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9
H
-fluorene-2-carboxamide HCl) was a selective D
3
antagonist, whereas CJB 090 (
N
-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide HCl) exhibited a partial agonist profile in both
in vitro
assays. In behavioral studies, the D
3
preferential agonist quinpirole (0.03–1.0 mg/kg, i.v.) dose-dependently elicited yawns in both groups of monkeys. PG 619 and CJB 090 elicited yawns only in monkeys with an extensive history of cocaine, whereas NGB 2904 did not elicit yawns, but did antagonize quinpirole and PG 619-elicited yawning in cocaine-history monkeys. In another experiment, doses of PG 619 that elicited yawns did not alter response rates in monkeys self-administering cocaine (0.03–0.3 mg/kg per injection). Following saline extinction, cocaine (0.1 mg/kg) and quinpirole (0.1 mg/kg), but not PG 619 (0.1 mg/kg), reinstated cocaine-seeking behavior. When given before a cocaine prime, PG 619 decreased cocaine-elicited reinstatement. These findings suggest that (1) an incongruence between
in vitro
and
in vivo
assays, and (2) a history of cocaine self-administration can affect
in vivo
efficacy of D
3
receptor-preferring compounds PG 619 and CJB 090, which appear to be dependent on the behavioral assay.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>21289600</pmid><doi>10.1038/npp.2010.248</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 2011-02, Vol.36 (5), p.1104-1113 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3070922 |
| source | Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 631/92/436/2387 692/699/476/5 Addictive behaviors Behavior Behavioral Sciences Biological and medical sciences Biological Psychology Cocaine Dopamine Drug abuse Medical research Medical sciences Medicine Medicine & Public Health Monkeys & apes Neuropharmacology Neurosciences Original original-article Pharmacology Pharmacology. Drug treatments Pharmacotherapy Physiology Psychiatry Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology |
| title | Influence of Cocaine History on the Behavioral Effects of Dopamine D3 Receptor-Selective Compounds in Monkeys |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T01%3A06%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20Cocaine%20History%20on%20the%20Behavioral%20Effects%20of%20Dopamine%20D3%20Receptor-Selective%20Compounds%20in%20Monkeys&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=Blaylock,%20B%20L&rft.date=2011-02-02&rft.volume=36&rft.issue=5&rft.spage=1104&rft.epage=1113&rft.pages=1104-1113&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/npp.2010.248&rft_dat=%3Cproquest_pubme%3E2293306511%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=857152260&rft_id=info:pmid/21289600&rfr_iscdi=true |